Ascendis Pharma A/S (ASND)
- Previous Close
159.39 - Open
159.45 - Bid 113.04 x 200
- Ask 195.77 x 200
- Day's Range
151.11 - 161.39 - 52 Week Range
111.09 - 183.00 - Volume
586,115 - Avg. Volume
555,181 - Market Cap (intraday)
9.131B - Beta (5Y Monthly) 0.40
- PE Ratio (TTM)
-- - EPS (TTM)
-6.56 - Earnings Date May 1, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
221.68
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
ascendispharma.comRecent News: ASND
View MorePerformance Overview: ASND
Trailing total returns as of 5/11/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ASND
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ASND
View MoreValuation Measures
Market Cap
9.13B
Enterprise Value
9.50B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
21.29
Price/Book (mrq)
--
Enterprise Value/Revenue
22.96
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-92.67%
Return on Assets (ttm)
-22.39%
Return on Equity (ttm)
--
Revenue (ttm)
368.7M
Net Income Avi to Common (ttm)
-341.68M
Diluted EPS (ttm)
-6.56
Balance Sheet and Cash Flow
Total Cash (mrq)
517.92M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-133.44M